Biogen BIIB announced that the FDA has approved a subcutaneous (SC) autoinjector version of Leqembi ... Iqlik after ...

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat ...

BioArctic’s partner Eisai receives US FDA approval for Leqembi IQLIK subcutaneous injection for maintenance dosing to treat early Alzheimer’s disease: Stockholm Monday, Septem ...

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the ...

The US Food and Drug Administration (FDA) on Friday approved a subcutaneous (SC) formulation of Biogen and Eisai’s Alzheimer’s disease treatment Leqembi (lecanemab), branded as Leqembi Iqlik, for ...

The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option ...

The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early ...

The researchers used insulin as a model because it’s a highly sought-after and expensive drug with lots of well-established ...

Known as CBL-514, this small-molecule drug induces adipocyte apoptosis, which kills fat cells rather than starves them, meaning different regions of subcutaneous fat stores can be rapidly reduced ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly ...

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless ...